Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Falk Roeder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3787-7386; OpenAlex author ID A5044726711. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2011: 1 paper, 1 trial · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: none · 2019: none · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Co-author DOI 10.1007/s00066-023-02085-7↗
  3. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Last author DOI 10.1016/j.radonc.2020.07.052↗
  4. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer. Co-author DOI 10.1016/j.ctro.2020.05.005↗
  5. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  6. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.03.040↗
  7. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  8. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  9. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Co-author DOI 10.1159/000455027↗
  10. Intraoperative radiation therapy (IORT) in pancreatic cancer. First author DOI 10.1186/s13014-016-0753-0↗
  11. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  12. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. Co-author DOI 10.4251/wjgo.v8.i2.186↗
  13. Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) i… Co-author DOI 10.1186/1471-2407-12-112↗
  14. Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospectiv… Co-author DOI 10.1186/1471-2407-12-295↗
  15. Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. Co-author DOI 10.1186/1471-2407-11-134↗

Trials 1

  1. Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer Principal investigator NCT01372735↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert C Krempien · 5 shared papers, 2012–2021 · strength 0.55
  2. Jens Werner · 6 shared papers, 1 shared trial, 2011–2020 · strength 0.35
  3. Frank W. Hensley · 4 shared papers, 2012–2020 · strength 0.30
  4. Michael Haas · 4 shared papers, 2016–2020 · strength 0.27
  5. Stephan Krüger · 4 shared papers, 2016–2020 · strength 0.27
  6. Stefan Hubert Boeck · 4 shared papers, 2016–2020 · strength 0.27
  7. Thomas Baptist Brunner · 2 shared papers, 2021–2023 · strength 0.25
  8. Philip M. Poortmans · 2 shared papers, 2020 · strength 0.24
  9. Felipe Ángel Calvo Manuel · 2 shared papers, 2020 · strength 0.24
  10. Marco Krengli · 2 shared papers, 2020 · strength 0.24
  11. José Manuel Asencio Pascual · 2 shared papers, 2020 · strength 0.24
  12. Volker Heinemann · 3 shared papers, 2016–2017 · strength 0.19
  13. Giuseppe Malleo · 2 shared papers, 2020 · strength 0.16
  14. Marko Damm · 2 shared papers, 2020 · strength 0.16
  15. John A. G. Moir · 2 shared papers, 2020 · strength 0.16
  16. Maximilian Weniger · 2 shared papers, 2020 · strength 0.16
  17. Patrick Maisonneuve · 2 shared papers, 2020 · strength 0.16
  18. Maximilian Kordes · 2 shared papers, 2020 · strength 0.16
  19. Laura Maggino · 2 shared papers, 2020 · strength 0.16
  20. Stephan Schorn · 2 shared papers, 2020 · strength 0.16
  21. Jan Goesta D’Haese · 2 shared papers, 2020 · strength 0.16
  22. Domenico Tamburrino · 2 shared papers, 2020 · strength 0.16
  23. Jonas Rosendahl · 2 shared papers, 2020 · strength 0.16
  24. Marco Del Chiaro · 2 shared papers, 2020 · strength 0.16
  25. Matthias J. Löhr · 2 shared papers, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.